实用医学杂志2011，Vol.27Issue(23)：4279-4282,4.DOI:10.3969/j.issn.1006-5725.2011.23.041
骨化三醇联合厄贝沙坦治疗IgA肾病的临床观察
Calcitriol plus irbesartan treatment for IgA nephropathy
摘要
Abstract
Objective To observe the efficacy and safety of 1 ,25 -dihydroxyvitamin D3 (calcitriol) plus irbesartan treatment for IgA nephropathy. Methods Forty-five patients with IgA nephropathy were randomly divided into calcitriol (VD3) group, irbesartan (ARB) group, and combination therapy (ARB+VD3) group. After treating for 8 weeks , the changes of urinary protein , renal function, serum calcium were measured. Results After the treatment, level of urine protein in ARB group was significantly decreased (P < 0.05) , and that in ARB+VD3 group was significantly decreased (P < 0.01) , and was significantly lower than those in ARB group and VD3 group (P< 0.05). All patients had no side effects or hypercalcemia. Conclusion Irbesartan plus calcitriol can effectively reduce the level of urinary protein in patients with IgA nephropathy, was more effective than single drug used, and had no significant adverse reactions.关键词
肾小球肾炎,IGA/骨化三醇/1,25－二羟维生素D3/厄贝沙坦Key words
Glomerulonephritis, IGA/Calcitriol/1,25-dihydroxyvitamin D3/Irbesartan引用本文复制引用
曾春,叶琨,龚智峰,伍秋霞,曾金盛,唐盛..骨化三醇联合厄贝沙坦治疗IgA肾病的临床观察[J].实用医学杂志,2011,27(23):4279-4282,4.基金项目
广西壮族自治区卫生厅科研课题( 编号:Z2009160) （ 编号:Z2009160）
